May 10, 2021
BioTissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Successfully Diagnose and Treat Mechanical Dry Eye
In conjunction with National Mechanical Dry Eye Day on May 19, 2021, Neel Desai, M.D. will host a special webinar to raise awareness about the management of Mechanical Dry Eye
Miami, FL – May 10, 2020 – BioTissue, Inc., a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue products, announced today that it would present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT. The webinar will be hosted by one of the nation’s foremost experts in Ocular Surface Disease (OSD), Neel Desai, MD. During the webinar, Dr. Desai will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to identify patients living with MDE and how to build physician practices by using Prokera® biologic corneal bandage devices and AmnioGraft® to facilitate the healing process and recovery for patients diagnosed with MDE.1
MDE in 3-D: Take A Closer Look webinar is free to health care professionals however, registration is required and can be done online. This groundbreaking webinar will require 3-D glasses for certain case studies presented during the program. Attendees will be able to request them by visiting the DiscoverMDE site (https://discovermde.com/mde-in-3d). BioTissue customers can also contact their local BioTissue representative to request their 3-D glasses or more information about the webinar.
“Reservoir Restoration is safe, relatively painless, and is performed in an outpatient setting. The procedure takes about 20 minutes and helps expedite the patient’s recovery by providing immediate and lasting relief, and promoting regenerative healing,” said TissueTech co-founder and Chief Technology Officer Scheffer C.G. Tseng, MD, Ph.D. With the new tissue in place, a reservoir of tears can form properly to keep the patient’s eye lubricated — thereby eliminating the symptoms that have been affecting them.” To learn more about MDE on #MDEin3D, visit BioTissue’s Facebook,LinkedIn, Instagram, and Twitter pages.
Mechanical Dry Eye is an age-related disorder often found in individuals over 60. This condition is also known as Conjunctivochalasis (CCh). It can be misdiagnosed or overlooked because the symptoms, including dryness, redness, eye pain, blurry vision, and excessive tearing, are similar to other types of ocular surface diseases. In fact, in a clinical study conducted by the National Institutes of Health (NIH), most CCh patients were diagnosed with more common ocular surface conditions, such as dry eye, blepharitis, or allergic eye disease, before the correct diagnosis.2
About BioTissue, Inc.
BioTissue, Inc. is a TissueTech, Inc. company. It is pioneering the clinical application of human birth tissue to promote regenerative healing for ocular surface disease and disorders. The BioTissue portfolio of cryopreserved amniotic membrane and umbilical cord products are processed using its proprietary CryoTek® technology to retain the birth tissue’s structural and functional integrity. As a leader in clinical research, BioTissue has been facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives since 1997. Connect with BioTissue on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.
About TissueTech, Inc.
TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane and umbilical cord products are processed using its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with the company’s products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://biotissue.com.
